296 related articles for article (PubMed ID: 20639885)
1. The C terminus of p53 binds the N-terminal domain of MDM2.
Poyurovsky MV; Katz C; Laptenko O; Beckerman R; Lokshin M; Ahn J; Byeon IJ; Gabizon R; Mattia M; Zupnick A; Brown LM; Friedler A; Prives C
Nat Struct Mol Biol; 2010 Aug; 17(8):982-9. PubMed ID: 20639885
[TBL] [Abstract][Full Text] [Related]
2. The hydrophobically-tagged MDM2-p53 interaction inhibitor Nutlin-3a-HT is more potent against tumor cells than Nutlin-3a.
Nietzold F; Rubner S; Berg T
Chem Commun (Camb); 2019 Nov; 55(95):14351-14354. PubMed ID: 31720601
[TBL] [Abstract][Full Text] [Related]
3. Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft.
Showalter SA; Bruschweiler-Li L; Johnson E; Zhang F; Brüschweiler R
J Am Chem Soc; 2008 May; 130(20):6472-8. PubMed ID: 18435534
[TBL] [Abstract][Full Text] [Related]
4. A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination.
Ma J; Martin JD; Zhang H; Auger KR; Ho TF; Kirkpatrick RB; Grooms MH; Johanson KO; Tummino PJ; Copeland RA; Lai Z
Biochemistry; 2006 Aug; 45(30):9238-45. PubMed ID: 16866370
[TBL] [Abstract][Full Text] [Related]
5. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin.
Hu B; Gilkes DM; Farooqi B; Sebti SM; Chen J
J Biol Chem; 2006 Nov; 281(44):33030-5. PubMed ID: 16905541
[TBL] [Abstract][Full Text] [Related]
6. Modulation of p53 C-terminal acetylation by mdm2, p14ARF, and cytoplasmic SirT2.
van Leeuwen IM; Higgins M; Campbell J; McCarthy AR; Sachweh MC; Navarro AM; Laín S
Mol Cancer Ther; 2013 Apr; 12(4):471-80. PubMed ID: 23416275
[TBL] [Abstract][Full Text] [Related]
7. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
8. Competitive binding between dynamic p53 transactivation subdomains to human MDM2 protein: implications for regulating the p53·MDM2/MDMX interaction.
Shan B; Li DW; Brüschweiler-Li L; Brüschweiler R
J Biol Chem; 2012 Aug; 287(36):30376-84. PubMed ID: 22807444
[TBL] [Abstract][Full Text] [Related]
9. Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies.
Joseph TL; Madhumalar A; Brown CJ; Lane DP; Verma CS
Cell Cycle; 2010 Mar; 9(6):1167-81. PubMed ID: 20190571
[TBL] [Abstract][Full Text] [Related]
10. Study on the spatial architecture of p53, MDM2, and p14ARF containing complexes.
Savchenko A; Yurchenko M; Snopok B; Kashuba E
Mol Biotechnol; 2009 Mar; 41(3):270-7. PubMed ID: 18989794
[TBL] [Abstract][Full Text] [Related]
11. The structure of an MDM2-Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant.
Anil B; Riedinger C; Endicott JA; Noble ME
Acta Crystallogr D Biol Crystallogr; 2013 Aug; 69(Pt 8):1358-66. PubMed ID: 23897459
[TBL] [Abstract][Full Text] [Related]
12. Monitoring Ligand-Induced Protein Ordering in Drug Discovery.
Grace CR; Ban D; Min J; Mayasundari A; Min L; Finch KE; Griffiths L; Bharatham N; Bashford D; Kiplin Guy R; Dyer MA; Kriwacki RW
J Mol Biol; 2016 Mar; 428(6):1290-1303. PubMed ID: 26812210
[TBL] [Abstract][Full Text] [Related]
13. Mdm2 is required for inhibition of Cdk2 activity by p21, thereby contributing to p53-dependent cell cycle arrest.
Giono LE; Manfredi JJ
Mol Cell Biol; 2007 Jun; 27(11):4166-78. PubMed ID: 17371838
[TBL] [Abstract][Full Text] [Related]
14. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
15. Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2.
Chee SM; Wongsantichon J; Soo Tng Q; Robinson R; Joseph TL; Verma C; Lane DP; Brown CJ; Ghadessy FJ
PLoS One; 2014; 9(8):e104914. PubMed ID: 25115702
[TBL] [Abstract][Full Text] [Related]
16. C-terminal region of USP7/HAUSP is critical for deubiquitination activity and contains a second mdm2/p53 binding site.
Ma J; Martin JD; Xue Y; Lor LA; Kennedy-Wilson KM; Sinnamon RH; Ho TF; Zhang G; Schwartz B; Tummino PJ; Lai Z
Arch Biochem Biophys; 2010 Nov; 503(2):207-12. PubMed ID: 20816748
[TBL] [Abstract][Full Text] [Related]
17. Identification of a second Nutlin-3 responsive interaction site in the N-terminal domain of MDM2 using hydrogen/deuterium exchange mass spectrometry.
Hernychova L; Man P; Verma C; Nicholson J; Sharma CA; Ruckova E; Teo JY; Ball K; Vojtesek B; Hupp TR
Proteomics; 2013 Aug; 13(16):2512-25. PubMed ID: 23776060
[TBL] [Abstract][Full Text] [Related]
18. Phosphomimetic mutation of the N-terminal lid of MDM2 enhances the polyubiquitination of p53 through stimulation of E2-ubiquitin thioester hydrolysis.
Fraser JA; Worrall EG; Lin Y; Landre V; Pettersson S; Blackburn E; Walkinshaw M; Muller P; Vojtesek B; Ball K; Hupp TR
J Mol Biol; 2015 Apr; 427(8):1728-47. PubMed ID: 25543083
[TBL] [Abstract][Full Text] [Related]
19. Molecular recognition of p53 and MDM2 by USP7/HAUSP.
Sheng Y; Saridakis V; Sarkari F; Duan S; Wu T; Arrowsmith CH; Frappier L
Nat Struct Mol Biol; 2006 Mar; 13(3):285-91. PubMed ID: 16474402
[TBL] [Abstract][Full Text] [Related]
20. S100 proteins interact with the N-terminal domain of MDM2.
van Dieck J; Lum JK; Teufel DP; Fersht AR
FEBS Lett; 2010 Aug; 584(15):3269-74. PubMed ID: 20591429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
